Published July 1, 2014 | Version v1
Journal article

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†

Contributors

Others:

Description

International audience

Additional details

Identifiers

URL
https://hal.science/hal-01626345
URN
urn:oai:HAL:hal-01626345v1

Origin repository

Origin repository
UNICA